Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 4 , Pages 353-360 , July 2008

Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer?

  • Gianluca Giannarini, M.D.

      Affiliations

    • Department of Urology, University of Pisa, Pisa, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 050 992081; fax: +39 050 992081.
    • ,
  • Cathryn A. Scott, M.D.

      Affiliations

    • Institute of Pathology, University of Udine, Udine, Italy
    • ,
  • Umberto Moro, M.D.

      Affiliations

    • Department of Urology, University of Udine, Udine, Italy
    • ,
  • Barbara Pertoldi, M.D.

      Affiliations

    • Institute of Pathology, University of Udine, Udine, Italy
    • ,
  • Carlo A. Beltrami, M.D.

      Affiliations

    • Institute of Pathology, University of Udine, Udine, Italy
    • ,
  • Cesare Selli, M.D.

      Affiliations

    • Department of Urology, University of Pisa, Pisa, Italy

Received 15 February 2007 ,Revised 5 April 2007 ,Accepted 6 April 2007.

References 

  1. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 1997;277:1445–1451
  2. D'Amico AV, Whittington R, Malkowicz SB, et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology. 1997;49(3A Suppl):23–30
  3. Wilkinson BA, Hamdy FC. State-of-the-art staging in prostate cancer. BJU Int. 2001;87:423–431
  4. Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147:817–821
  5. Kalish J, Cooner WH, Graham SD. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology. 1994;43:601–606
  6. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentrations vs. prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J Urol. 1994;152:2031–2036
  7. Cookson MS, Floyd MK, Ball TP, et al. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol. 1995;154:1070–1073
  8. Zlotta AR, Djavan B, Marberger M, et al. Prostate specific antigen density of the transition zone: A new effective parameter for prostate cancer prediction. J Urol. 1997;157:1315–1321
  9. Lin DW, Gold MH, Ransom S, et al. Transition zone prostate specific antigen density: Lack of use in prediction of prostatic carcinoma. J Urol. 1998;160:77–81
  10. Horninger W, Reissigl A, Klocker H, et al. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate. 1998;37:133–137
  11. Kikuchi E, Nakashima J, Ishibashi M, et al. Prostate specific antigen adjusted for transition zone volume (The most powerful method for detecting prostate carcinoma). Cancer. 2000;89:842–849
  12. Shinohara K, Wolf JS, Narayan P, et al. Comparison of prostate specific antigen with prostate specific antigen density for three clinical applications. J Urol. 1994;152:120–123
  13. Wolff JM, Boeckmann W, Effert PJ, et al. Clinical use of prostate-specific antigen and prostate-specific antigen density in the staging of patients with cancer of the prostate. Eur Urol. 1996;30:451–457
  14. Zlotta AR, Djavan B, Petein M, et al. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/ml. J Urol. 1998;160:2089–2095
  15. Kurita Y, Suzuki A, Masuda H, et al. Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels. Eur Urol. 1998;33:32–38
  16. Horninger W, Rogatsch H, Reissigl A, et al. Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening. Prostate. 1999;40:56–61
  17. Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56:255–260
  18. Furuya Y, Ohta S, Sato N, et al. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels. Anticancer Res. 2001;21:1317–1320
  19. Horiguchi A, Nakashima J, Horiguchi Y, et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate. 2003;56:23–29
  20. Brassell SA, Kao TC, Sun L, et al. Prostate-specific antigen vs. prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005;66:1229–1233
  21. Nathan MS, Seenivasagam K, Mei Q, et al. Transrectal ultrasonography: Why are estimates of prostate volume and dimension so inaccurate?. Br J Urol. 1996;77:401–407
  22. Baltaci S, Yagci C, Aksoy H, et al. Determination of transition zone volume by transrectal ultrasound in patients with clinically benign prostatic hyperplasia: Agreement with enucleated prostate adenoma weight. J Urol. 2000;164:72–75
  23. Dähnert WF. Determination of prostate volume with transrectal US for cancer screening. Radiology. 1992;183:625–626
  24. Tong S, Cardinal HN, McLoughlin RF, et al. Intra- and inter-observer variability and reliability of prostate volume measurement via two-dimensional and three-dimensional ultrasound imaging. Ultrasound Med Biol. 1998;24:673–681
  25. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations. Prostate. 1983;4:473–485
  26. Sobin LH, Wittekind C. TNM classification of malignant tumors. In: 5th ed.. New York: Wiley-Liss; 1997;p. 170–173
  27. Djavan B. PSA and repeat biopsy. In:  Brawer MK editors. Prostate specific antigen. New York: Marcel Dekker; 2001;p. 159–174
  28. Sebo TJ, Bock BJ, Cheville JC, et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000;163:174–178
  29. Grossklaus DJ, Coffey CS, Shappell SB, et al. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol. 2002;167:2032–2036
  30. Lewis JS, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol. 2002;118:442–450

PII: S1078-1439(07)00101-9

doi: 10.1016/j.urolonc.2007.04.002

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 4 , Pages 353-360 , July 2008

Article Tools

* Image Usage & Resolution